IMS 2026 Conference Intelligence

Heading to #IMS26 ! Going through all the amazing abstracts, A few things on my radar this year so far: — CERVINO: first phase 3 readout for a BCMA bispecific vs standard-of-care in triple-class exposed RRMM — PERSEUS at 6+ years — does the PFS advantage for quad induction hold up long-term, and is there finally an OS signal? — Two separate first-in-human reports of in vivo CAR-T generation — no apheresis, no lymphodepletion. If this works, it changes how we think about access to cellular therapy entirely. — CARTITUDE-2 5-year data on cilta-cel in earlier-line RRMM — EXCALIBER-RRMM: iberdomide's first phase President of IMS - Prof Phillip Moreau and his executive team, @myelomaMD @mvmateos @NoopurRajeMD @NikhilMunshiMD have put together an amazing meeting with 669 abstracts and many amazing talks ! I will be tweeting important practice changing abstract through rest of week; excited for busy week :) #Myeloma #HemOnc #IMS2026 #glasgow

Heading to #IMS26 ! Going through all the amazing abstracts, A few things on my radar this year so far: — CERVINO: first phase 3 readout for a BCMA bispecific vs standard-of-care in triple-class exposed RRMM — PERSEUS at 6+ years — does the PFS advantage for quad induction hold up long-term, and is there finally an OS signal? — Two separate first-in-human reports of in vivo CAR-T generation — no apheresis, no lymphodepletion. If this works, it changes how we think about access to cellular therapy entirely. — CARTITUDE-2 5-year data on cilta-cel in earlier-line RRMM — EXCALIBER-RRMM: iberdomide's first phase President of IMS - Prof Phillip Moreau and his executive team, @myelomaMD @mvmateos @NoopurRajeMD @NikhilMunshiMD have put together an amazing meeting with 669 abstracts and many amazing talks ! I will be tweeting important practice changing abstract through rest of week; excited for busy week :) #Myeloma #HemOnc #IMS2026 #glasgow

Heading to #IMS26 ! Going through all the amazing abstracts, A few things on my radar this year so far: — CERVINO: first phase 3 readout for a BCMA bispecific vs standard-of-care in triple-class exposed RRMM — PERSEUS at 6+ years — does the PFS advantage for quad induction hold up long-term, and is there finally an OS signal? — Two separate first-in-human reports of in vivo CAR-T generation — no apheresis, no lymphodepletion. If this works, it changes how we think about access to cellular therapy entirely. — CARTITUDE-2 5-year data on cilta-cel in earlier-line RRMM — EXCALIBER-RRMM: iberdomide's first phase President of IMS - Prof Phillip Moreau and his executive team, @myelomaMD @mvmateos @NoopurRajeMD @NikhilMunshiMD have put together an amazing meeting with 669 abstracts and many amazing talks ! I will be tweeting important practice changing abstract through rest of week; excited for busy week :) #Myeloma #HemOnc #IMS2026 #glasgow